Skip to main content
AUPH
NASDAQ Life Sciences

Aurinia Q2: LUPKYNIS Sales Climb 19% to $79.4M, Net Income Soars 74%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$15.849
Mkt Cap
$1.953B
52W Low
$10.34
52W High
$19.25
52W Position info
53% above low
Off High info
18% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AUPH sits 53% above its 52-week low of $10.34.

Summary

Aurinia reported Q2 2026 revenue of $83.2 million, up 19%, driven by LUPKYNIS sales of $79.4 million. Net income rose 74% to $37.4 million, and the company reiterated full-year guidance of $315–$325 million in total revenue.


Key Events · Earnings and Guidance · AUPH

  • LUPKYNIS Sales Accelerate

    Net product sales of LUPKYNIS reached $79.4 million in Q2 2026, a 19% increase year-over-year, driven by growing demand for the first FDA-approved oral therapy for active lupus nephritis.

  • Profitability Surges

    Net income jumped 74% to $37.4 million, with diluted EPS of $0.28, reflecting strong operating leverage and a 19% increase in operating cash flow to $52.5 million.

  • Robust Cash Position

    Cash, cash equivalents, restricted cash and investments totaled $443.1 million as of June 30, 2026, after repurchasing 5.0 million shares for $74.9 million during the first half of the year.

  • Full-Year Guidance Reiterated

    Management reaffirmed 2026 total revenue guidance of $315–$325 million and net product sales guidance of $305–$315 million, implying 11–15% growth over 2025.


Analysis · AUPH · Life Sciences

A strong second quarter saw LUPKYNIS net product sales accelerate to $79.4 million, a 19% year-over-year gain that lifted total revenue to $83.2 million. Net income surged 74% to $37.4 million, and the company generated $52.5 million in operating cash flow for the period. The balance sheet remains robust with $443.1 million in cash and investments, even after repurchasing $74.9 million in shares. Management reiterated full-year revenue guidance of $315–$325 million, signaling confidence in sustained growth. The pipeline also advanced, with the initiation of a Phase 4 combination study for LUPKYNIS and clinical development of aritinercept in four autoimmune indications. These results reinforce Aurinia's transition to a profitable, cash-generating commercial-stage biotech.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AUPH was trading at $15.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.34 to $19.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AUPH - Latest Insights

AUPH
Oct 30, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.62
Real-time Price: $15.49 info
Change: -$1.13 (-7%) info
Market Cap: $2.074B info
AUPH
Oct 30, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $17.21
Real-time Price: $15.49 info
Change: -$1.72 (-10%) info
Market Cap: $2.074B info
AUPH
Aug 19, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.34
Real-time Price: $15.49 info
Change: -$0.850 (-5%) info
Market Cap: $2.074B info
AUPH
Aug 19, 2026, 4:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.57
Real-time Price: $15.49 info
Change: -$1.08 (-7%) info
Market Cap: $2.074B info
AUPH
Aug 06, 2026, 8:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $15.49 info
Change: -$0.260 (-2%) info
Market Cap: $2.074B info